Hematological toxicity evaluation of the PARP inhibitor- fluzopril in a wide population of ovarian cancer based on active monitoring mode

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300078644

Enrollment

Unknown

Registered

2023-12-14

Start date

2023-12-30

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Case series :NA

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Prior to the commencement of any study-specific procedure, a written informed consent form signed and signed by the patient or legal representative must be provided. (2) Patients diagnosed with fluzoparib approved tumor types, including recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer. (3) According to the judgment of the treating doctor in clinical practice, fluzoparib can be used for treatment. (4) Take at least one dose of fluzoparib before enrollment.

Exclusion criteria

Exclusion criteria: Have participated in this study or other ongoing studies prior to enrollment, and are judged by investigators to be unable to participate in this non-interventional study.

Design outcomes

Primary

Measure	Time frame
AE;	—

Secondary

Measure	Time frame
PFS;OS;ORR;	—

Countries

China

Contacts

Public ContactYu Lei

Guangxi Medical University Affiliated Cancer Hospital

1147112852@qq.com+86 152 7718 2937

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026